{"transactions":[{"id":4616746,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:03.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":919,"price":33.1488,"value":30463.7472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.855  to $33.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3613123,"source":{"system":"sec-edgar","filing":"0001193125-26-390507","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526390507/ownership.xml","form_type":"4"}},{"id":4616745,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:03.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":29545,"price":32.1557,"value":950040.1565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.81 to $32.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3614042,"source":{"system":"sec-edgar","filing":"0001193125-26-390507","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526390507/ownership.xml","form_type":"4"}},{"id":680064,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:03.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":60039,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":3643587,"source":{"system":"sec-edgar","filing":"0001193125-26-359675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526359675/ownership.xml","form_type":"4"}},{"id":853786,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-09T20:00:10.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":373295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":373295,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":373295},"source":{"system":"sec-edgar","filing":"0001193125-26-098440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526098440/ownership.xml","form_type":"4"}},{"id":853785,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:10.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":248865,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3583548,"source":{"system":"sec-edgar","filing":"0001193125-26-098440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526098440/ownership.xml","form_type":"4"}},{"id":862078,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:10.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":29282,"price":14.484,"value":424120.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.160. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3334683,"source":{"system":"sec-edgar","filing":"0001193125-26-091442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526091442/ownership.xml","form_type":"4"}},{"id":919626,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:05:16.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":15500,"price":14.6834,"value":227592.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3363965,"source":{"system":"sec-edgar","filing":"0001193125-26-037552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526037552/ownership.xml","form_type":"4"}},{"id":935520,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":false,"shares":2818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. The option is due to expire on February 19, 2026."}],"balance_after":0,"derivative":{"exercise_price":7.57,"expiration_date":"2026-02-19","underlying":"Common Stock","underlying_shares":2818},"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935519,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":false,"shares":197182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. The option is due to expire on February 19, 2026."}],"balance_after":2818,"derivative":{"exercise_price":7.57,"expiration_date":"2026-02-19","underlying":"Common Stock","underlying_shares":197182},"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935518,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-16","kind":"sale","planned":false,"acquired":false,"shares":1974,"price":13.8293,"value":27299.0382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.82 to $13.835. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3379465,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935517,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":true,"shares":2818,"price":7.57,"value":21332.26,"ownership":{"direct":true},"balance_after":3381439,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935516,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":136193,"price":13.5895,"value":1850794.7735,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3378621,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935515,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":true,"shares":197182,"price":7.57,"value":1492667.74,"ownership":{"direct":true},"balance_after":3514814,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":943366,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:05:12.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":7715,"price":11.0948,"value":85596.382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.05 to $11.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3317632,"source":{"system":"sec-edgar","filing":"0001193125-26-007666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526007666/ownership.xml","form_type":"4"}},{"id":1027590,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:10.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":200,"price":14.9975,"value":2999.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.995 to $15.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3325347,"source":{"system":"sec-edgar","filing":"0001193125-25-228340","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312525228340/ownership.xml","form_type":"4"}},{"id":1027589,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:10.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":29733,"price":14.3433,"value":426469.3389,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3325547,"source":{"system":"sec-edgar","filing":"0001193125-25-228340","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312525228340/ownership.xml","form_type":"4"}},{"id":1183911,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-02T20:57:43.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":21490,"price":3.4659,"value":74482.191,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.435 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3355280,"source":{"system":"sec-edgar","filing":"0000950170-25-049513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025049513/ownership.xml","form_type":"4"}},{"id":1215366,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T00:28:36.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":270177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":270177,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":270177},"source":{"system":"sec-edgar","filing":"0000950170-25-036708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025036708/ownership.xml","form_type":"4"}},{"id":1215365,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:28:36.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":180118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3376770,"source":{"system":"sec-edgar","filing":"0000950170-25-036708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025036708/ownership.xml","form_type":"4"}},{"id":1223048,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:32:37.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":4595,"price":3.1663,"value":14549.1485,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.09 to $3.195. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3196652,"source":{"system":"sec-edgar","filing":"0000950170-25-033719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025033719/ownership.xml","form_type":"4"}},{"id":1282229,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-05T21:55:39.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":11851,"price":3.4687,"value":41107.5637,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.46 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3201247,"source":{"system":"sec-edgar","filing":"0000950170-25-014610","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025014610/ownership.xml","form_type":"4"}},{"id":1306905,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-08T22:26:01.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":7471,"price":4.0466,"value":30232.1486,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.99 to $4.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3213098,"source":{"system":"sec-edgar","filing":"0000950170-25-003531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025003531/ownership.xml","form_type":"4"}},{"id":1394818,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-02T22:53:51.000Z","date":"2024-09-30","kind":"sale","planned":false,"acquired":false,"shares":18589,"price":3.1962,"value":59414.1618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.12 to $3.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3220569,"source":{"system":"sec-edgar","filing":"0000950170-24-111811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024111811/ownership.xml","form_type":"4"}},{"id":1399557,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-25T21:56:10.000Z","date":"2024-09-23","kind":"exercise","planned":false,"acquired":false,"shares":1857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.57,"expiration_date":"2025-02-26","underlying":"Common Stock","underlying_shares":1857},"source":{"system":"sec-edgar","filing":"0000950170-24-109397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024109397/ownership.xml","form_type":"4"}},{"id":1399556,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-25T21:56:10.000Z","date":"2024-09-23","kind":"exercise","planned":false,"acquired":true,"shares":1857,"price":1.57,"value":2915.49,"ownership":{"direct":true},"balance_after":3239158,"source":{"system":"sec-edgar","filing":"0000950170-24-109397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024109397/ownership.xml","form_type":"4"}},{"id":1406800,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-16T21:39:13.000Z","date":"2024-09-12","kind":"exercise","planned":false,"acquired":false,"shares":34449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":1857,"derivative":{"exercise_price":1.57,"expiration_date":"2025-02-26","underlying":"Common Stock","underlying_shares":34449},"source":{"system":"sec-edgar","filing":"0000950170-24-106915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024106915/ownership.xml","form_type":"4"}},{"id":1406799,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-16T21:39:13.000Z","date":"2024-09-12","kind":"exercise","planned":false,"acquired":true,"shares":34449,"price":1.57,"value":54084.93,"ownership":{"direct":true},"balance_after":3237301,"source":{"system":"sec-edgar","filing":"0000950170-24-106915","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024106915/ownership.xml","form_type":"4"}},{"id":1539310,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-19T00:21:31.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":380000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0000950170-24-045696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024045696/ownership.xml","form_type":"4"}},{"id":1539309,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-19T00:21:31.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":179850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3202852,"source":{"system":"sec-edgar","filing":"0000950170-24-045696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024045696/ownership.xml","form_type":"4"}},{"id":1589418,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-07T21:05:17.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":4135,"price":18.7279,"value":77439.8665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3023002,"source":{"system":"sec-edgar","filing":"0000950170-24-027923","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024027923/ownership.xml","form_type":"4"}},{"id":1612686,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T23:22:38.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":190000,"derivative":{"exercise_price":17.56,"expiration_date":"2034-02-25","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0000950170-24-022413","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024022413/ownership.xml","form_type":"4"}},{"id":1612685,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-28T23:22:38.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":126667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":3027137,"source":{"system":"sec-edgar","filing":"0000950170-24-022413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024022413/ownership.xml","form_type":"4"}},{"id":1680911,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-11T22:10:55.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":5841,"price":16.3281,"value":95372.4321,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2900470,"source":{"system":"sec-edgar","filing":"0000950170-24-003981","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017024003981/ownership.xml","form_type":"4"}},{"id":1734894,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-21T01:20:39.000Z","date":"2023-11-16","kind":"exercise","planned":false,"acquired":false,"shares":63694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25,012 shares subject to such option vested and became exercisable on February 26, 2021, with the remaining shares vesting in monthly installments of 2,083 shares thereafter."}],"balance_after":36306,"derivative":{"exercise_price":1.57,"expiration_date":"2025-02-26","underlying":"Common Stock","underlying_shares":63694},"source":{"system":"sec-edgar","filing":"0000950170-23-065259","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017023065259/ownership.xml","form_type":"4"}},{"id":1734893,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-21T01:20:39.000Z","date":"2023-11-16","kind":"exercise","planned":false,"acquired":true,"shares":63694,"price":1.57,"value":99999.58,"ownership":{"direct":true},"balance_after":2906311,"source":{"system":"sec-edgar","filing":"0000950170-23-065259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017023065259/ownership.xml","form_type":"4"}},{"id":1944820,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-21T00:21:04.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":225000,"derivative":{"exercise_price":32.08,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-23-009171","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924323009171/doc4.xml","form_type":"4"}},{"id":1944819,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:21:04.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":2842617,"source":{"system":"sec-edgar","filing":"0000899243-23-009171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924323009171/doc4.xml","form_type":"4"}},{"id":1944818,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:21:04.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":3924,"price":32.4451,"value":127314.5724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.26 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2792617,"source":{"system":"sec-edgar","filing":"0000899243-23-009171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924323009171/doc4.xml","form_type":"4"}},{"id":1944817,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:21:04.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":96076,"price":31.8396,"value":3059021.4096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2796541,"source":{"system":"sec-edgar","filing":"0000899243-23-009171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924323009171/doc4.xml","form_type":"4"}},{"id":2057671,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-11T00:20:58.000Z","date":"2023-01-06","kind":"sale","acquired":true,"shares":1846,"price":36.7888,"value":67912.1248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2892617,"source":{"system":"sec-edgar","filing":"0000899243-23-001524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924323001524/doc4.xml","form_type":"4"}},{"id":2057670,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-11T00:20:58.000Z","date":"2023-01-06","kind":"sale","acquired":true,"shares":4122,"price":36.0789,"value":148717.2258,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2894463,"source":{"system":"sec-edgar","filing":"0000899243-23-001524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924323001524/doc4.xml","form_type":"4"}},{"id":2279511,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-06T20:05:26.000Z","date":"2022-05-05","kind":"exercise","acquired":false,"shares":334520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.37,"expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":334520},"source":{"system":"sec-edgar","filing":"0000899243-22-017083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924322017083/doc4.xml","form_type":"4"}},{"id":2279510,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-06T20:05:26.000Z","date":"2022-05-05","kind":"exercise","acquired":true,"shares":334520,"price":0.37,"value":123772.4,"ownership":{"direct":true},"balance_after":2898585,"source":{"system":"sec-edgar","filing":"0000899243-22-017083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924322017083/doc4.xml","form_type":"4"}},{"id":2439023,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-11T01:32:06.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":337500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":337500,"derivative":{"exercise_price":19,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":337500},"source":{"system":"sec-edgar","filing":"0000899243-22-001518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924322001518/doc4.xml","form_type":"4"}},{"id":2439022,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Series C-1 Preferred Stock","published_at":"2022-01-11T01:32:06.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":4870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4870},"source":{"system":"sec-edgar","filing":"0000899243-22-001518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924322001518/doc4.xml","form_type":"4"}},{"id":2439021,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-11T01:32:06.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":2564065,"source":{"system":"sec-edgar","filing":"0000899243-22-001518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924322001518/doc4.xml","form_type":"4"}},{"id":2439020,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-11T01:32:06.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":4870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."}],"balance_after":2489065,"source":{"system":"sec-edgar","filing":"0000899243-22-001518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000089924322001518/doc4.xml","form_type":"4"}}]}